EP Patent

EP1047421A2 — Inhibition of lipoprotein oxidation

Assigned to Warner Lambert Co LLC · Expires 2000-11-02 · 26y expired

What this patent protects

Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.

USPTO Abstract

Hydroxylated derivatives of cholesterol lowering agents inhibit the oxidation of lipoproteins, and are thus useful for preventing the progression of atherogenesis and resultant vascular diseases, including heart attacks.

Drugs covered by this patent

Patent Metadata

Patent number
EP1047421A2
Jurisdiction
EP
Classification
—
Expires
2000-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Warner Lambert Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.